/CAI

CAI Stock - Caris Life Sciences, Inc.

Q: What is the analyst price target for CAI?

Analyst price target information is not currently available for CAI.

Q: What is CAI's market cap?

Market capitalization information is not currently available for CAI.

Healthcare|Biotechnology|NASDAQ

$26.40+3.13%

+$0.80 (+3.13%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+21.2%upside

Target: $32.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CAI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-1.58

52W High$42.50

52W Low$22.86

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2020	FY2019
Revenue	$412.26M	$306.13M	$258.49M	$294.01M	$416.54M
Gross Profit	$178.78M	$89.31M	$80.02M	$184.16M	$200.51M
Gross Margin	43.4%	29.2%	31.0%	62.6%	48.1%
Operating Income	$-257,122,000	$-319,551,000	$-315,756,000	$139.09M	$130.28M
Net Income	$-281,890,000	$-341,415,000	$-320,827,000	$27.73M	$31.01M
Net Margin	-68.4%	-111.5%	-124.1%	9.4%	7.4%
EPS	$-2.70	$-1.82	$-1.57	$1.55	$1.72

Company Overview

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Visit Website

Earnings History & Surprises

CAI

Beat Rate

50%

Last 2 quarters

Avg Surprise

+21.4%

EPS vs Estimate

Beats / Misses

1/1

Last 12 quarters

Latest EPS

$0.08

Q4 2025

EPS Surprise History

Q3 25

-157.1%

$-0.54vs$-0.21

Q4 25

+200.0%

$0.08vs$-0.08

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 5, 2025	$-0.08	$0.08	+200.0%	✓ BEAT
Q3 2025	Aug 12, 2025	$-0.21	$-0.54	-157.1%	✗ MISS

Frequently Asked Questions about CAI

What is CAI's current stock price?

Caris Life Sciences, Inc. (CAI) is currently trading at $26.40 per share. The stock has moved +3.13% today.

What is the analyst price target for CAI?

The average analyst price target for CAI is $32.00, based on 1 analyst.

What sector is Caris Life Sciences, Inc. in?

Caris Life Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CAI's market cap?

Caris Life Sciences, Inc. has a market capitalization of $7.45 billion, making it a mid-cap company.

Does CAI pay dividends?

No, Caris Life Sciences, Inc. does not currently pay a dividend to shareholders.